TABLE 1.
Antibiogram of the novel HL-AZMR isolatesa
| N. gonorrhoeae isolate | MIC (μg/ml)b
|
β-Lactamase | Sample type | ||||||
|---|---|---|---|---|---|---|---|---|---|
| AZM | CFM | CRO | CIP | GEN | PEN | TET | |||
| AZMR-16 | 4 & ≥256 | 0.06 | 0.03 | 0.015 | 8 | 1 | 1 | Negative | Urethral |
| AZMR-16-MCc | ≥256 | 0.06 | 0.03 | ND | ND | ND | ND | Negative | |
| AZMR-18 | ≥256 | 0.06 | 0.06 | 16 | 4 | 1 | 4 | Negative | Urethral |
| AZMR-19A | ≥256 | 0.03 | 0.015 | 0.015 | 8 | 0.25 | 1 | Negative | Pharyngeal |
| AZMR-19B | 4 & ≥256 | 0.03 | 0.015 | 0.03 | 8 | 0.25 | 2 | Negative | Rectal |
| AZMR-19B-MCd | ≥256 | 0.03 | 0.015 | ND | ND | ND | ND | Negative | |
a
Antimicrobial susceptibility profile of N. gonorrhoeae isolates harboring the A2058G mutation in the 23S rRNA. Isolates with the A2058G mutation were HL-AZMR. These isolates displayed varying levels of susceptibility to other antibiotics.
b
ND, not determined.
c
Laboratory N. gonorrhoeae strain derived from clinical strain AZMR-16.
d
Laboratory N. gonorrhoeae strain derived from clinical strain AZMR-19B.